Clinical Trial Update: A Study of Lenvatinib, Pembrolizumab, and Fulvestrant in People With Breast Cancer [Phase 1, Phase 2]

View source ↗

Summary

A phase 1/2 clinical trial evaluating the combination of lenvatinib, pembrolizumab, and fulvestrant in metastatic breast cancer is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Faslodex (fulvestrant)
• KEYTRUDA (PEMBROLIZUMAB)
• LENVIMA (lenvatinib)

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Metastatic Breast Cancer | Phase 1, Phase 2 | Status: RECRUITING